Latest News

Manchester, UK and Mountain View, Calif, August 27, 2024 – Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, announced that the first patient has been dosed in the second part of a Phase 2 proof-of-concept, randomized, placebo-controlled clinical study in chronic cough with AX-8, its lead compound. AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel. The company has raised additional financing from existing and new investors to support the trial execution and Phase 3 planning.

Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort

Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort

AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough

TRPM8 Pathway May Play Antitussive and Counterirritant Role in Chronic Cough; Data Expected Mid 2022

Axalbion will soon start recruitment for a Phase 2 study to assess the efficacy and safety of AX-8 in patients with chronic cough.

Axalbion therapeutics Limited, Axalbion SA's parent company, has been incorporated in UK, 24 February 2021.

Dr. Kitt joined Axalbion as Chief Executive Officer in November 2019, bringing more than 30 years of clinical development experience and industry expertise.

Results of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:

If you need further information please feel free to contact us.